2023-507504-31-00招募中1 期
A PHASE-1, FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, FOOD EFFECT, AND DRUG-DRUG INTERACTION OF ORALLY ADMINISTERED VENT-03 IN HEALTHY VOLUNTEERS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 84
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Ofer Spiegelstein
Scientific
Ventus Therapeutics U.S. Inc.
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled,Single and Multiple Ascending Intravenous Dose Study toAssess the Safety, Tolerability, Pharmacokinetics of VGL101 in HealthyAdultsACTRN12622000933752Vigil Neuroscience, Inc60
已完成
不适用
A First in Human, Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Total Daily Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Intravenous Infusion of OMN6 in Healthy SubjectsNL-OMON51720Omnix Medical104
已完成
1 期
A study to investigate the safety and concentration in the blood and urine of different dose strengths of OCT461201 in healthy volunteersISRCTN39003837Oxford Cannabinoids Technologies Ltd.32
已完成
1 期
A Phase I study in healthy adults to investigate the safety and tolerability of an oral formulation of A3907Safety, tolerability, pharmacokinetics and pharmacodynamics of an oral formulation of A3907ISRCTN17748514Albireo (Sweden)75
已完成
不适用
A FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE AND MULTIPLE ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS (INCLUDING FOOD EFFECT) OF IMB1018972 IN HEALTHY SUBJECTSischemic cardiovascular disease10019280heart failureNL-OMON48517Imbria Pharmaceuticals, Inc.128